Human IL-17A&IL-17F Heterodimer Protein, Twin Strep&His Tag (MALS verified)
分子別名（Synonym）
IL-17A, Interleukin-17A, CTLA-8, IL-17, IL-17F, Interleukin-17F, Cytokine ML-1, IL17A＆IL17F
表達區(qū)間及表達系統(tǒng)（Source）
Human IL-17A&IL-17F Heterodimer Protein, Twin Strep&His Tag (ILF-H52W6) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Ala 155 (IL-17A) & Arg 31 - Gln 163 (IL-17F) (Accession # Q16552-1 (IL-17A) & Q96PD4-1 (IL-17F)). Two sequential affinity purification steps were used to ensure exact 1:1 molar ratio of IL17A＆IL17F heterodimer.
Predicted N-terminus: Trp (IL-17A) & His (IL-17F)
蛋白結構（Molecular Characterization）
Human IL-17A&IL-17F Heterodimer Protein, Twin Strep&His Tag, produced by co-expression of IL-17A and IL-17F, has a calculated MW of 18.5 kDa (IL-17A) and 16.8 kDa (IL-17F). Subunit IL-17A is fused with a Twin Strep tag at the N-terminus and subunit IL-17F is fused with a polyhistidine tag at the N-terminus. The protein migrates as 19-27 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method / rFC method.
純度（Purity）
>90% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介紹
白細胞介素17A（IL17A）亦稱細胞毒性T淋巴細胞相關抗原8（CTLA8），是一種由活化T細胞產(chǎn)生的促炎細胞因子。該細胞因子可調(diào)控核因子κB（NF-κB）和絲裂原活化蛋白激酶的活性，同時能促進IL6和環(huán)氧化酶2（PTGS2/COX-2）的表達，并增強一氧化氮（NO）的生成。此外，研究發(fā)現(xiàn)IL17A存在糖基化和非糖基化兩種形式。IL-17水平升高與類風濕關節(jié)炎、銀屑病、多發(fā)性硬化等多種慢性炎癥疾病密切相關。
關鍵字： IL-17A&IL-17F;IL-17A蛋白;IL-17F重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領域提供關鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。